HER2-Positive Early Breast Cancer
Symposium
Symposium

HER2-Positive Early Breast Cancer

A Personalized Approach to Treatment

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

Interact with expert faculty in Barcelona at our symposium, HER2-Positive Breast Cancer: A Personalized Approach to Treatment. During this live activity, experts will discuss the biology of HER2-positive breast cancer, the role of neoadjuvant therapy for HER2-positive early breast cancer, and risk-adapted treatments for HER2-positive early breast cancer. Come with your pressing questions about the management of patients in this setting.

ESMO 2019 Industry Satellite Symposium

Date and Location

Saturday, 28 September 2019
18:30 – 20:00

Cartagena Auditorium, Hall 3
Fira Gran Via
Barcelona, Spain

Date/Time

Date/Time

Saturday, 28 September 2019
18:30 – 20:00

Location

Location

Barcelona, Spain

IME

IME

18:30 Welcome and introduction
Martine Piccart, MD, PhD
18:32 “Test your knowledge” interactive quiz
Martine Piccart, MD, PhD
18:35 Getting to grips with the biology of HER2-positive breast cancer
Sara Hurvitz, MD, FACP
18:50 Q&A
18:55 Neoadjuvant treatment strategies for HER2-positive early breast cancer: Should treatment recommendations be response-based?
Sibylle Loibl, MD, PhD
19:15 Q&A
19:20 Risk-adapted treatments for HER2-positive early breast cancer
Javier Cortés, MD, PhD
19:40 Q&A
19:45 Developing a roadmap for the treatment of HER2-positive early breast cancer: One size no longer fits all
Martine Piccart, MD, PhD
19:55 Conclusions and prIME Points™
Martine Piccart, MD, PhD
20:00 Adjourn

Faculty

    Chair

  • Martine Piccart, MD, PhDJules Bordet Institute
    Brussels, Belgium
  • Faculty

  • Javier Cortés, MD, PhDIOB Institute of Oncology, Madrid and Barcelona
    Vall d'Hebron Institute of Oncology (VHIO)
    Medica Scientia Innovation Research (MedSIR)
    Barcelona, Spain
  • Sara Hurvitz, MD, FACPUniversity of California, Los Angeles
    UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California, United States
  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany

This educational activity is designed for oncologists, gynecologists, breast surgeons, and other healthcare professionals who are interested in and/or involved in the treatment of breast cancer and wish to understand how to apply some of the latest developments in treatments for HER2-positive early breast cancer into routine clinical practice.

After successful completion of this educational activity, participants should be able to:

  • Describe the interactions of HER2 signaling with other biologic and immunologic pathways
  • Select the optimal HER2-targeted strategy to improve long-term disease endpoints in patients with HER2-positive early breast cancer
  • Define a risk adapted approach for when to either de-escalate or intensify HER2 targeted treatments

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Sunshine Act/EFPIA

prIME, a Medscape Oncology Company complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.